Abstract
Background Corona Virus Disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China since late December 2019. Crude case fatality ratio (CFR) with dividing the number of known deaths by the number of confirmed cases does not represent the true CFR and might be off by orders of magnitude. We aim to provide a precise estimate of the CFR of COVID-19 using statistical models at the early stage of the epidemic.
Methods We extracted data from the daily released epidemic report published by the National Health Commission P. R. China from 20 Jan 2020, to 22 Feb 2020. Competing risk model was used to obtain the cumulative hazards for death, cure, and cure-death hazard ratio. Then the CFR was estimated based on the slope of the last piece in joinpoint regression model, which reflected the most recent trend of the epidemic.
Results As of 22 Feb 2020, totally 77,041 cases were diagnosed as COVID-19 in China. The CFR of COVID-19 were estimated to be 7.24% (95% CI: 6.61%-8.01%) in Hubei province, including Wuhan, the epicenter, and 1.00% (95% CI: 0.87%-1.18%) in other areas of China, respectively. We observed obvious decreasing trends of CFR for COVID-19, with three distinct turning points on January 30, February 6, and February 15 for Hubei province, and one turning point on February 8 for other areas, respectively.
Conclusions Based on analyses of public data, we found that the CFR in Hubei was much higher than that of other regions in China, over 7 times in all estimation. The CFR would follow a downwards trend based on our estimation from recently released data. Nevertheless, at early stage of outbreak, CFR estimates should be viewed cautiously because of limited data source on true onset and recovery time.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for the research reported in the article.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data, models, and code generated or used during the study appear in the submitted article.
